A phase 2 trial was designed with a combination of Berzosertib (M6620), an ATP-competitive ATR inhibitor, and topotecan in SCLC patients who had relapsed after at least one prior chemotherapy. This evidence concerns the gene ATR and small cell lung carcinoma.